Shanmuga Hospital Board Approves Audited FY26 Results; Net Profit at ₹421.06 Lakhs

6 min read     Updated on 11 May 2026, 10:43 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Shanmuga Hospital Limited's board approved audited FY26 results with net profit of ₹421.06 lakhs and revenue from operations of ₹4,743.61 lakhs. The board re-appointed M/s J V & Co., Chartered Accountants (FRN: 006382S), Salem, as internal auditors for FY 2026-27 under Regulation 30 of SEBI (LODR) Regulations, effective May 11, 2026. Additionally, the board voluntarily committed to quarterly financial reporting from FY 2026-27 to enhance investor transparency.

powered bylight_fuzz_icon
40059867

*this image is generated using AI for illustrative purposes only.

Shanmuga Hospital Limited's Board of Directors convened on Monday, May 11, 2026, and approved the audited financial results for the half year and full year ended March 31, 2026, in compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory audit was conducted by M/s PPN & Company, Chartered Accountants (FRN: 013623S), Chennai, who issued an unmodified audit opinion on the annual audited financial results. The meeting commenced at 03:00 PM and concluded at 05:10 PM.

Financial Performance: Full Year and Half Year Ended March 31, 2026

The company reported steady financial performance for the full year ended March 31, 2026. Revenue from operations stood at ₹4,743.61 lakhs for the year ended March 31, 2026, compared to ₹4,785.33 lakhs in the previous year. Total income, including other income of ₹62.71 lakhs, amounted to ₹4,806.32 lakhs against ₹4,808.67 lakhs in the prior year. Net profit for the full year was ₹421.06 lakhs, marginally higher than ₹420.67 lakhs recorded in the previous year.

The following table presents the Statement of Profit and Loss for the periods under review:

Particulars: H2 FY26 (Audited) H1 FY26 (Unaudited) H2 FY25 (Audited) FY26 (Audited) FY25 (Audited)
Revenue From Operations: ₹2,281.54 lakhs ₹2,462.07 lakhs ₹2,323.15 lakhs ₹4,743.61 lakhs ₹4,785.33 lakhs
Other Income: ₹52.77 lakhs ₹9.94 lakhs ₹2.72 lakhs ₹62.71 lakhs ₹23.35 lakhs
Total Income: ₹2,334.31 lakhs ₹2,472.01 lakhs ₹2,325.87 lakhs ₹4,806.32 lakhs ₹4,808.67 lakhs
Total Expenses: ₹2,037.62 lakhs ₹2,201.68 lakhs ₹2,080.73 lakhs ₹4,239.30 lakhs ₹4,239.93 lakhs
Profit Before Tax: ₹296.69 lakhs ₹270.33 lakhs ₹245.14 lakhs ₹567.02 lakhs ₹568.74 lakhs
Net Profit: ₹219.93 lakhs ₹201.13 lakhs ₹181.38 lakhs ₹421.06 lakhs ₹420.67 lakhs
Basic EPS (₹): 1.62 1.48 1.64 3.09 4.03
Diluted EPS (₹): 1.62 1.48 1.64 3.09 4.03

All amounts in Rs. Lakhs. EPS not annualised for half year ended results.

Key Expense Highlights

For the full year ended March 31, 2026, the major expense components were as follows:

Expense Head: FY26 (Audited) FY25 (Audited)
Cost of Consumption: ₹1,474.72 lakhs ₹1,772.74 lakhs
Employee Benefits Expense: ₹757.98 lakhs ₹559.25 lakhs
Finance Costs: ₹42.15 lakhs ₹62.67 lakhs
Depreciation & Amortisation: ₹281.65 lakhs ₹215.80 lakhs
Other Expenses: ₹1,682.79 lakhs ₹1,629.47 lakhs

Balance Sheet Overview as at March 31, 2026

The company's total assets and liabilities stood at ₹5,305.70 lakhs as at March 31, 2026, compared to ₹5,278.10 lakhs as at March 31, 2025. Key balance sheet items are summarised below:

Particulars: As at 31st March, 2026 As at 31st March, 2025
Share Capital: ₹1,361.30 lakhs ₹1,361.30 lakhs
Reserves and Surplus: ₹2,888.89 lakhs ₹2,608.51 lakhs
Long-Term Borrowings: ₹359.35 lakhs ₹359.35 lakhs
Deferred Tax Liabilities (Net): ₹104.92 lakhs ₹41.35 lakhs
Long-Term Provisions: ₹29.29 lakhs ₹11.04 lakhs
Short-Term Borrowings: ₹314.43 lakhs ₹402.10 lakhs
Trade Payables (MSMEs): - ₹12.11 lakhs
Trade Payables (Other Creditors): ₹206.27 lakhs ₹366.04 lakhs
Other Current Liabilities: ₹40.51 lakhs ₹115.59 lakhs
Property, Plant & Equipment: ₹3,746.89 lakhs ₹2,242.71 lakhs
Intangible Assets: ₹16.85 lakhs -
Capital Work in Progress: ₹244.08 lakhs -
Inventories: ₹195.77 lakhs ₹288.97 lakhs
Cash & Cash Equivalents: ₹192.52 lakhs ₹1,258.93 lakhs
Trade Receivables: ₹685.73 lakhs ₹796.05 lakhs
Short-term Loans and Advances: ₹117.97 lakhs ₹628.02 lakhs
Total Assets/Liabilities: ₹5,305.70 lakhs ₹5,278.10 lakhs

Cash Flow Summary for the Year Ended March 31, 2026

The company generated net cash from operating activities of ₹1,231.42 lakhs for the year ended March 31, 2026, compared to a net cash outflow of ₹(156.94) lakhs in the previous year. Net cash used in investing activities was ₹(2,032.73) lakhs, primarily on account of purchase of property, plant and equipment amounting to ₹(2,046.76) lakhs. Net cash used in financing activities was ₹(265.10) lakhs, which included issue expenses for the initial public offer of ₹(140.68) lakhs and net repayment in short-term borrowings of ₹(87.67) lakhs, resulting in a net decrease in cash and cash equivalents of ₹(1,066.41) lakhs during the year. Closing cash and cash equivalents stood at ₹192.52 lakhs as at March 31, 2026.

Cash Flow Activity: FY26 FY25
Net Cash from Operating Activities: ₹1,231.42 lakhs ₹(156.94) lakhs
Net Cash Used in Investing Activities: ₹(2,032.73) lakhs ₹(433.50) lakhs
Net Cash Used in Financing Activities: ₹(265.10) lakhs ₹1,639.46 lakhs
Net Increase/(Decrease) in Cash: ₹(1,066.41) lakhs ₹1,049.02 lakhs
Closing Cash & Cash Equivalents: ₹192.52 lakhs ₹1,258.93 lakhs

Internal Auditor Re-appointment and Governance Decisions

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the board approved the re-appointment of M/s J V & Co., Chartered Accountants (FRN: 006382S), Salem, as Internal Auditors of the company for the financial year 2026-27, effective May 11, 2026. The key details of the re-appointment are as follows:

Parameter: Details
Name of Auditor: M/s J V & Co., Chartered Accountants
Firm Registration No.: FRN: 006382S
Reason: Re-appointment as Internal Auditor
Date of Appointment: May 11, 2026
Term: Financial Year 2026-27
Head Office: Salem
Branch Office: Tirupur

The firm has over thirty years of professional experience across valuations, internal audits, statutory audits, tax audits, transfer pricing audits, payroll audits, and stock audits, and is empanelled with the Comptroller and Auditor General (CAG) of India (Empanelment No. SR 0889) for audits of government and public sector undertakings. The firm comprises four partners — K. Jambunathan (FCA, DISA, PGDFM, CAAT), K. Vasudevan (FCA, CAAT), S. Narendran (FCA, DISA, PGDHR, CAAT), and R. Ahalya (FCA) — supported by a team of 16 staff and articled clerks.

Quarterly Reporting Commitment

In a significant governance development, the board voluntarily resolved to declare and submit financial results on a quarterly basis commencing from FY 2026-27. Although Shanmuga Hospital's equity shares are listed on the BSE SME Platform — where submission of quarterly financial results is not mandatory under SEBI (LODR) Regulations, 2015 — the board has chosen to adopt this practice in the interest of enhanced investor transparency and good corporate governance. The statutory auditor M/s PPN & Company, Chartered Accountants, issued an audit report with an unmodified opinion on the annual audited financial results for the half year and financial year ended March 31, 2026.

Historical Stock Returns for Shanmuga Hospital

1 Day5 Days1 Month6 Months1 Year5 Years
-7.10%-9.37%-10.22%-0.08%-1.87%-27.56%

How will the significant capital expenditure of ₹2,046.76 lakhs on property, plant and equipment translate into revenue growth and capacity expansion in FY2027?

With employee benefits expenses rising 35.5% year-over-year, what talent acquisition or retention strategy is Shanmuga Hospital pursuing, and could this pressure margins in the near term?

Will the voluntary adoption of quarterly financial reporting attract institutional investors and potentially support a transition from the BSE SME Platform to the main board?

Shanmuga Hospital Limited Schedules Board Meeting for May 11, 2026 to Approve Q4FY26 Financial Results

1 min read     Updated on 30 Apr 2026, 12:27 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Shanmuga Hospital Limited has scheduled a board meeting for May 11, 2026, at its Salem registered office to approve audited financial results for Q4FY26. The company has closed its trading window from April 1, 2026, which will remain closed until 48 hours after results declaration. The meeting agenda includes consideration of audited financial results for the quarter and year ended March 31, 2026, along with other business matters.

powered bylight_fuzz_icon
39077835

*this image is generated using AI for illustrative purposes only.

Shanmuga Hospital Limited has informed the stock exchanges about an upcoming board meeting scheduled for May 11, 2026, to approve its audited financial results for the quarter and year ended March 31, 2026. The announcement was made through a formal intimation to BSE Limited on April 30, 2026.

Board Meeting Details

The board meeting will be conducted at the company's registered office located at 51/24 Saradha College Road, Salem - 636 007. The meeting has been scheduled in accordance with Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Parameter: Details
Meeting Date: Monday, May 11, 2026
Venue: Registered Office, Salem
Primary Agenda: Audited Financial Results for Q4FY26
Regulatory Compliance: SEBI LODR Regulation 29(1)(a)

Meeting Agenda

The board will primarily focus on considering and approving the audited financial results for the fourth quarter and full year ended March 31, 2026. Additionally, the agenda includes provision for any other business matters that may be taken up with the permission of the chairperson.

Trading Window Closure

In compliance with insider trading regulations, Shanmuga Hospital Limited has implemented a trading window closure for dealing in the company's securities. The trading window has been closed with effect from April 1, 2026, and will continue to remain closed until 48 hours after the declaration of the audited financial results.

Corporate Communication

The intimation was signed by Kannan Anjana Maragatham, Company Secretary & Compliance Officer, who holds membership number A70080. The communication was digitally signed and submitted to ensure proper regulatory compliance and transparency with stakeholders.

Historical Stock Returns for Shanmuga Hospital

1 Day5 Days1 Month6 Months1 Year5 Years
-7.10%-9.37%-10.22%-0.08%-1.87%-27.56%

What impact will Shanmuga Hospital's Q4FY26 results have on its expansion plans in the competitive Tamil Nadu healthcare market?

How might the hospital's financial performance influence its ability to invest in advanced medical equipment and technology upgrades?

Will Shanmuga Hospital consider strategic partnerships or acquisitions following the release of its annual results?

More News on Shanmuga Hospital

1 Year Returns:-1.87%